Certara, Inc. (NASDAQ:CERT) Receives $15.17 Average Target Price from Analysts

Certara, Inc. (NASDAQ:CERT - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $15.17.

A number of equities research analysts have recently commented on the company. Barclays lowered their price objective on Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Robert W. Baird upped their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. William Blair reiterated a "market perform" rating on shares of Certara in a report on Thursday, February 27th. TD Cowen assumed coverage on shares of Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price for the company. Finally, Stephens reaffirmed an "overweight" rating and set a $17.00 price target on shares of Certara in a research note on Thursday, February 27th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CERT. Kopion Asset Management LLC raised its stake in shares of Certara by 46.0% in the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock valued at $5,918,000 after acquiring an additional 175,005 shares during the period. Principal Financial Group Inc. increased its holdings in Certara by 3.1% in the 4th quarter. Principal Financial Group Inc. now owns 531,445 shares of the company's stock valued at $5,660,000 after purchasing an additional 15,739 shares in the last quarter. Vontobel Holding Ltd. purchased a new position in Certara in the fourth quarter valued at about $1,295,000. Barclays PLC lifted its stake in shares of Certara by 198.3% during the third quarter. Barclays PLC now owns 70,525 shares of the company's stock worth $825,000 after purchasing an additional 46,880 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Certara in the fourth quarter worth about $3,628,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Trading Down 1.3 %

CERT stock traded down $0.19 during midday trading on Friday, hitting $14.27. The stock had a trading volume of 2,506,225 shares, compared to its average volume of 1,206,586. The company's 50-day moving average price is $11.65 and its 200 day moving average price is $11.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The firm has a market cap of $2.30 billion, a PE ratio of -71.33, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. Certara has a 12-month low of $8.64 and a 12-month high of $17.94.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.